Macrolide treatment does not influence serum homocysteine in Chlamydia pneumoniae-seropositive patients suffering from atherosclerosis [5]

Clinical Chemistry

Volumn 48, Issue 9, 2002, Pages 1631-

  Schulthess, Georg ^a   Wiesli, Peter ^a   Maly, Friedrich E ^a  

^a UNIVERSITÄTSSPITAL ZÜRICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HOMOCYSTEINE; MACROLIDE; PLACEBO; ROXITHROMYCIN;

ANTIBIOTIC THERAPY; ATHEROSCLEROSIS; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERHOMOCYSTEINEMIA; LETTER; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RISK FACTOR; SMOKING;

CHLAMYDIA; CHLAMYDOPHILA; CHLAMYDOPHILA PNEUMONIAE;

EID: 0036721596     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/48.9.1631     Document Type: Letter

References (5)

1. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction
2. Homocysteine and atherothrombosis
3. Chlamydia pneumoniae seropositivity and hyperhomocysteinemia are linked in patients with atherosclerosis
4. Roxithromycin treatment prevents progression of peripheral arterial occlusive disease in Chlamydia pneumoniae seropositive men: A randomized, double-blind, placebo-controlled trial
5. Amino acid requirements for growth of Chlamydia pneumoniae in cell cultures: Growth enhancement by lysine or methionine depletion